✦ LIBER ✦

Antituberculosis drug-induced hepatitis and HBsAg carriers

✍ Scribed by Amarapurkar, D.N.; Prabhudesai, P.P.; Kairo, R.H.; Desai, H.G.

Book ID: 123473459
Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 227 KB
Volume: 74
Category: Article
ISSN: 0962-8479
DOI: 10.1016/0962-8479(93)90017-R

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TNF-α genetic polymorphism −308G/A and a

TNF-α genetic polymorphism −308G/A and antituberculosis drug-induced hepatitis

✍ Sang-Heon Kim; Sang-Hoon Kim; Ho Joo Yoon; Dong Ho Shin; Sung Soo Park; Youn-Seu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB

Cytochrome P450 2E1 genotype and the sus

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis

✍ Yi-Shin Huang; Herng-Der Chern; Wei-Juin Su; Jaw-Ching Wu; Shi-Chuan Chang; Chi- 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

SUSCEPTIBILITY OF CHRONIC SYMPTOMLESS HB

SUSCEPTIBILITY OF CHRONIC SYMPTOMLESS HBsAg CARRIERS TO ETHANOL-INDUCED HEPATIC DAMAGE

✍ Villa, Erica; Barchi, Tiziana; Grisendi, A.; Bellentani, S.; Rubbiani, Lorenza; 📂 Article 📅 1982 🏛 The Lancet 🌐 English ⚖ 279 KB

Hepatitis b surface antigen (hbsag) in p

Hepatitis b surface antigen (hbsag) in peritoneal fluid of hbsag carriers undergoing peritoneal dialysis

✍ Richard J. Salo; Ann A. Salo; Wilson J. Fahlberg; Joanne T. Ellzey 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 368 KB 👁 1 views

Monitoring and management of antitubercu

Monitoring and management of antituberculosis drug induced hepatotoxicity

✍ SUBHASH AGAL; RAJIV BAIJAL; SNEHANSHU PRAMANIK; NIKHIL PATEL; PARIJAT GUPTE; PRA 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

Monitoring and management of antitubercu

Monitoring and management of antituberculosis drug induced hepatotoxicity

✍ SUBHASH AGAL; RAJIV BAIJAL; SNEHANSHU PRAMANIK; NIKHIL PATEL; PARIJAT GUPTE; PRA 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract **Background:** Hepatotoxicity to antituberculosis therapy (ATT) poses a major challenge. This often results in inadequate therapy. The risk of fulminant hepatic failure and mortality is high once icteric hepatitis develops. There is no consensus on monitoring protocols and for the rein